PA8567201A1 - Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la cicloxigenasa-2 - Google Patents

Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la cicloxigenasa-2

Info

Publication number
PA8567201A1
PA8567201A1 PA20038567201A PA8567201A PA8567201A1 PA 8567201 A1 PA8567201 A1 PA 8567201A1 PA 20038567201 A PA20038567201 A PA 20038567201A PA 8567201 A PA8567201 A PA 8567201A PA 8567201 A1 PA8567201 A1 PA 8567201A1
Authority
PA
Panama
Prior art keywords
alfa
delta
binding
combinations
cycloxigenasa
Prior art date
Application number
PA20038567201A
Other languages
English (en)
Spanish (es)
Inventor
Charles Price Taylor Jr
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PA8567201A1 publication Critical patent/PA8567201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PA20038567201A 2002-02-22 2003-02-21 Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la cicloxigenasa-2 PA8567201A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35929502P 2002-02-22 2002-02-22
US40436502P 2002-08-19 2002-08-19

Publications (1)

Publication Number Publication Date
PA8567201A1 true PA8567201A1 (es) 2003-11-12

Family

ID=27760521

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038567201A PA8567201A1 (es) 2002-02-22 2003-02-21 Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la cicloxigenasa-2

Country Status (21)

Country Link
US (1) US20030199567A1 (enExample)
EP (1) EP1480639A1 (enExample)
JP (1) JP2005523281A (enExample)
KR (1) KR20040085216A (enExample)
CN (1) CN1635887A (enExample)
AR (1) AR038531A1 (enExample)
AU (1) AU2003246864A1 (enExample)
BR (1) BR0307906A (enExample)
CA (1) CA2476438A1 (enExample)
CO (1) CO5611109A2 (enExample)
HN (1) HN2003000071A (enExample)
IL (1) IL162932A0 (enExample)
MX (1) MXPA04008175A (enExample)
NO (1) NO20043947L (enExample)
PA (1) PA8567201A1 (enExample)
PE (1) PE20031052A1 (enExample)
PL (1) PL372210A1 (enExample)
RU (1) RU2286151C2 (enExample)
TW (1) TW200303214A (enExample)
UY (1) UY27675A1 (enExample)
WO (1) WO2003070237A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2341240T3 (es) * 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
JP2006520799A (ja) * 2003-03-21 2006-09-14 ダイノジェン ファーマシューティカルズ， インコーポレイテッド 平滑筋調節因子およびα２δサブユニットカルシウムチャネル調節因子を用いた、下部尿路障害を処置するための方法
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
AU2004271800A1 (en) * 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
WO2005041976A2 (en) * 2003-10-23 2005-05-12 Medtronic, Inc. Injectable gabapentin compositions
EP2007723A2 (en) * 2006-04-11 2008-12-31 Novartis AG Organic compounds
CN101610761A (zh) * 2006-12-22 2009-12-23 诺瓦提斯公司 作为ddp-iv抑制剂的1-氨基甲基-l-苯基-环己烷衍生物
CA2723358A1 (en) * 2008-05-05 2009-11-12 Allison B. Reiss Method for improving cardiovascular risk profile of cox inhibitors
SI2331210T1 (sl) * 2008-09-05 2014-10-30 Gruenenthal Gmbh Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika
KR102631399B1 (ko) * 2018-03-30 2024-02-01 씨지인바이츠 주식회사 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
CA3200132A1 (en) * 2020-10-28 2022-05-05 Tremeau Pharmaceuticals, Inc. Aqueous formulations of water insoluble cox-2 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234929A (en) * 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5420270A (en) * 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5352638A (en) * 1994-02-22 1994-10-04 Corning Incorporated Nickel aluminosilicate glass-ceramics
HU0102041D0 (en) * 1994-07-27 2001-07-30 Warner Lambert Co Pharmacological compounds which bind to [3h]-gabapentine binding protein
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
WO1999012537A1 (en) * 1997-09-08 1999-03-18 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
IL135315A0 (en) * 1997-12-16 2001-05-20 Warner Lambert Co 4(3)-substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (gabapentin analogues), their preparation and their use in the treatment of neurological disorders
CA2359485A1 (en) * 1999-03-10 2000-09-14 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
BR0008059A (pt) * 1999-12-08 2002-03-26 Pharmacia Corp Composições de valdecoxib

Also Published As

Publication number Publication date
AR038531A1 (es) 2005-01-19
UY27675A1 (es) 2003-09-30
CO5611109A2 (es) 2006-02-28
MXPA04008175A (es) 2004-11-26
NO20043947L (no) 2004-09-21
TW200303214A (en) 2003-09-01
CN1635887A (zh) 2005-07-06
EP1480639A1 (en) 2004-12-01
AU2003246864A1 (en) 2003-09-09
WO2003070237A1 (en) 2003-08-28
HN2003000071A (es) 2003-11-24
JP2005523281A (ja) 2005-08-04
PE20031052A1 (es) 2003-12-24
RU2004125609A (ru) 2006-01-27
RU2286151C2 (ru) 2006-10-27
PL372210A1 (en) 2005-07-11
BR0307906A (pt) 2004-12-21
KR20040085216A (ko) 2004-10-07
IL162932A0 (en) 2005-11-20
CA2476438A1 (en) 2003-08-28
US20030199567A1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
PA8567201A1 (es) Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la cicloxigenasa-2
AR022023A1 (es) Combinaciones de inhibidores del transporte de acido ileo-biliar con derivados del acido fibrico para prescripciones cardiovasculares
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
DE60317564D1 (de) Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten
BRPI0011172B8 (pt) derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2
PA8506101A1 (es) Uso de un compuesto acat para fabricar una composicion farmaceutica
PA8592101A1 (es) Nuevos enantiomeros (r) y (s) de derivados del acido tiofeno hidroxamico
PA8541601A1 (es) Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7.
ECSP088984A (es) Derivados de triazol ii
AR022022A1 (es) Combinaciones de inhibidores del transporte de acido ileo-biliar con agentes secuestrantes de acido biliar, para prescripciones cardiovasculares
UY27481A1 (es) Alquinos como inhibidores de metaloproteinasa de matriz
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
ECSP034896A (es) Derivados aromaticos de acidos dicarboxilicos
CR10983A (es) 6-alquiliden-penems biciclicos como inhibidores de b-lactamasas (divisional)
ITVR20020062A1 (it) Preparazione estemporanea di periossiacidi organici stabili nel tempo
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
CL2022002148A1 (es) Inhibidores heterocíclicos de pad4
UY26889A1 (es) Compuestos farmacéuticos
PE20210928A1 (es) Mezclas pesticidas que comprenden indazoles
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
CL2025000445A1 (es) Inhibidores de kif18a y usos de estos
GT200000221A (es) Inhibidores de la proteinasa c del procolageno.
MXPA04001398A (es) Metodo para el tratamiento y prevencion de dolor e inflamacion con glucosamina y un inhibidor selectivo de ciclooxigenasa-2 y composiciones para el mismo.
AR112217A1 (es) Una combinación de un inhibidor de mps1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
AR022321A1 (es) Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada